Editor's note: This blog was updated on July 24, 2018.

When FDA approved two CAR T-cell therapies last year, it caused a groundswell of excitement across the country—but many questions remain around implementation and reimbursement. Keep reading to learn how one leading cancer center has reorganized its services to improve care for immunotherapy patients and how barriers to CAR T reimbursement are raising concerns about access.